EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety and Efficacy of Concurrent Atezolizumab/Bevacizumab or Nivolumab Combination Therapy with Yttrium-90 Radioembolization of Advanced Unresectable Hepatocellular Carcinoma

Alexander Villalobos iD, Howard Hussein Dabbous iD, Olivia Little iD, Olumide Babajide Gbolahan, Mehmet Akce, Meghan Allegra Lilly, Zachary Bercu, Nima Kokabi

Current Oncology · 2023

DOI: 10.3390/curroncol30120734 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2023. Verfasst von Alexander Villalobos und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, University of North Carolina at Chapel Hill, Alexander Villalobos 101 Manning Drive, Chapel Hill, NC 27514, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Sirtex (Germany).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To evaluate the safety and efficacy of combining yttrium-90 radioembolization (Y90-RE) with immune checkpoint inhibitor therapy, consecutive advanced unresectable hepatocellular carcinoma (HCC) patients treated between 2016 and 2022 with atezolizumab/bevacizumab or nivolumab within three-months pre- and post-Y90-RE were retrospectively evaluated. Tumor response and treatment-related clinical/laboratory adverse events (AE) were assessed at 1 and 6 months, as well as differences in clinical and laboratory variables and median overall survival (OS) from initial treatment (whether it was Y90-RE or systemic therapy) between the two cohorts. A total of 19 patients (10 atezolizumab/bevacizumab; 9 nivolumab), comprising 84% males with median age 69 years, met the inclusion criteria. Compared to the atezolizumab/bevacizumab group, there were less males (100% vs. 67%; p = 0.02) and more ECOG ≥ 2 patients in the nivolumab group (0% vs. 33%; p = 0.02). Baseline characteristics or incidence of 6-month post-treatment any-grade AE (60% vs. 56%; p = 0.7), grade ≥ 3 AE (0% vs. 11%; p = 0.3), objective response (58% total, 60% vs. 56%; p = 0.7), and complete response (16% total; 10% vs. 22%; p = 0.8) were similar between the atezolizumab/bevacizumab and the nivolumab cohorts. Median OS was 12.9 months for the whole cohort, 16.4 months for nivolumab, and 10.7 months for atezolizumab/bevacizumab. Among patients with advanced unresectable HCC, the utilization of Y90-RE concurrently or within 90 days of nivolumab or atezolizumab/bevacizumab immunotherapy, appears to be well-tolerated and with a low incidence of severe AE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsMaleHumansAgedFemaleBevacizumabNivolumabRetrospective StudiesYttrium RadioisotopesAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

SIRTY90 radioembolizationanti-PD-L1atezolizumabbevacizumabhepatocellular carcinomaimmune checkpoint inhibitorsnivolumab

Substanzen

BevacizumabNivolumabYttrium-90Yttrium RadioisotopesatezolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Radiology, University of North Carolina at Chapel Hill, Alexander Villalobos 101 Manning Drive, Chapel Hill, NC 27514, USA.
  • Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Department of Radiology and Imaging Sciences, Mercer University School of Medicine, Savannah, GA 31404, USA.
  • Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Department of Hematology and Medical Oncology, University of Alabama School of Medicine, Birmingham, AL 35294, USA.

ORCID-Profile: Alexander Villalobos, Howard Hussein Dabbous, Olivia Little

Förderung

  • NCI NIH HHS
  • Sirtex (Germany)

Zitieren

APA

Villalobos, A., Dabbous, H. H., Little, O., Gbolahan, O. B., Akce, M., Lilly, M. A., Bercu, Z., & Kokabi, N. (2023). Safety and Efficacy of Concurrent Atezolizumab/Bevacizumab or Nivolumab Combination Therapy with Yttrium-90 Radioembolization of Advanced Unresectable Hepatocellular Carcinoma. Current Oncology. https://doi.org/10.3390/curroncol30120734

Vancouver

Villalobos A, Dabbous HH, Little O, Gbolahan OB, Akce M, Lilly MA, et al. Safety and Efficacy of Concurrent Atezolizumab/Bevacizumab or Nivolumab Combination Therapy with Yttrium-90 Radioembolization of Advanced Unresectable Hepatocellular Carcinoma. Current Oncology. 2023. doi:10.3390/curroncol30120734

BibTeX
@article{Villalobos2023,
  author = {Villalobos, Alexander and Dabbous, Howard Hussein and Little, Olivia and Gbolahan, Olumide Babajide and Akce, Mehmet and Lilly, Meghan Allegra and Bercu, Zachary and Kokabi, Nima},
  title = {Safety and Efficacy of Concurrent Atezolizumab/Bevacizumab or Nivolumab Combination Therapy with Yttrium-90 Radioembolization of Advanced Unresectable Hepatocellular Carcinoma},
  journal = {Current Oncology},
  year = {2023},
  doi = {10.3390/curroncol30120734}
}
Kostenlos starten →